← Eichor
Condition: Autoimmune Hemolytic Anemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Autoimmune Hemolytic Anemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
EARLY_Phase 1 · 1 location(s) · The Second Hospital of Anhui Medical University · NCT07530380French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT02877706Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Phase 1/Phase 2 · 10 location(s) · CRISPR Therapeutics AG · NCT07549698Orelabrutinib in the Treatment of Relapsed/Refractory AIHA
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07453368FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Phase N/A · 1 location(s) · xCures · NCT06539169Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Phase N/A · 7 location(s) · Alexion Pharmaceuticals, Inc. · NCT06312644Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06921980Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (w
Phase 2 · 25 location(s) · Novartis Pharmaceuticals · NCT07039422A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06653556OM336 in Autoimmune Cytopenias
Phase 1 · 3 location(s) · Lakefront Biotherapeutics West LLC · NCT07083960National Longitudinal Cohort of Hematological Diseases
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04645199Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07578675IASO-782 in Autoimmune Hematological Diseases
Phase 1 · 2 location(s) · Shanghai IASO Biotechnology Co., Ltd · NCT06534021National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07019038Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-p
EARLY_Phase 1 · 2 location(s) · Grit Biotechnology · NCT07205315Safety Study of CC312 in Autoimmune Disease Patients
EARLY_Phase 1 · 1 location(s) · CytoCares Inc · NCT06888960Sirolimus in the Treatment of Refractory/Relapsed wAIHA
NA · 1 location(s) · Peking Union Medical College Hospital · NCT05925023Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic An
Phase 2 · 1 location(s) · Centre Hospitalier Universitaire Dijon · NCT05089227Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Phase N/A · 1 location(s) · Paul Szabolcs · NCT04528355Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Phase 2 · 3 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT05694312Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Phase 3 · 2 location(s) · Assiut University · NCT05057468Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07361094Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for
EARLY_Phase 1 · 1 location(s) · Circunited BioPharma (Shenzhen) Co., Ltd. · NCT07629596A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
Phase 1/Phase 2 · 3 location(s) · Keymed Biosciences Co.Ltd · NCT07175493National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Partici
Phase 3 · 95 location(s) · Sanofi · NCT07086976UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07441525OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Phase N/A · 9 location(s) · University Hospital, Bordeaux · NCT05937828Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia
Phase N/A · 1 location(s) · University Hospital, Bordeaux · NCT04005638
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.